BACKGROUND: Strong racial discrepancies in end-stage renal disease exist. Whether there are race differences in kidney function loss in younger healthy persons is not well established. STUDY DESIGN: Longitudinal. SETTING & PARTICIPANTS: 3,348 black and white adults with at least 2 measurements of cystatin C-based estimated glomerular filtration rate (eGFRcys) at scheduled Coronary Artery Risk Development in Young Adults (CARDIA) examinations (years 10, 15, and 20). PREDICTOR: Race. OUTCOMES & MEASUREMENTS: We used linear mixed models to examine race differences in annualized rates of eGFRcys decline, adjusting for age, sex, lifetime exposure to systolic blood pressure >120 mm Hg, diabetes, and albumin-creatinine ratio. We used Poisson regression to compare racial differences in rapid decline (eGFRcys decline >3% per year) by study period (10-15 years after baseline examination [defining period 1] and >15-20 years after baseline examination [defining period 2]). RESULTS: Mean age was 35 ± 3.6 (SD) years, and mean eGFRcys was 110 ± 20 mL/min/1.73 m² for blacks and 104 ± 17 mL/min/1.73 m² for whites at baseline. For both blacks and whites, eGFRcys decline was minimal at younger ages (<35 years) and eGFRcys loss accelerated at older ages. However, acceleration of eGFRcys decline occurred at earlier ages for blacks than whites. Blacks had somewhat faster annualized rates of decline compared with whites, but differences were attenuated after adjustment in period 1 (0.13 mL/min/1.73 m² per year faster; P = 0.2). In contrast, during period 2, blacks had significantly faster annualized rates of decline, even after adjustment (0.32 mL/min/1.73 m² per year faster; P = 0.003). The prevalence of rapid decline was significantly higher for blacks versus whites, with prevalence rate ratios of 1.31 (95% CI, 1.04-1.63) for period 1 and 1.24 (95% CI, 1.09-1.41) for period 2. Differences were attenuated after full adjustment: adjusted prevalence rate ratios were 1.20 (95% CI, 0.95-1.49) for period 1 and 1.10 (95% CI, 0.96-1.26) for period 2. LIMITATIONS: No measured GFR. CONCLUSIONS: eGFRcys decline differs by race at early ages, with faster annualized rates of decline for blacks. Future studies are required to explain the observed differences.
BACKGROUND: Strong racial discrepancies in end-stage renal disease exist. Whether there are race differences in kidney function loss in younger healthy persons is not well established. STUDY DESIGN: Longitudinal. SETTING & PARTICIPANTS: 3,348 black and white adults with at least 2 measurements of cystatin C-based estimated glomerular filtration rate (eGFRcys) at scheduled Coronary Artery Risk Development in Young Adults (CARDIA) examinations (years 10, 15, and 20). PREDICTOR: Race. OUTCOMES & MEASUREMENTS: We used linear mixed models to examine race differences in annualized rates of eGFRcys decline, adjusting for age, sex, lifetime exposure to systolic blood pressure >120 mm Hg, diabetes, and albumin-creatinine ratio. We used Poisson regression to compare racial differences in rapid decline (eGFRcys decline >3% per year) by study period (10-15 years after baseline examination [defining period 1] and >15-20 years after baseline examination [defining period 2]). RESULTS: Mean age was 35 ± 3.6 (SD) years, and mean eGFRcys was 110 ± 20 mL/min/1.73 m² for blacks and 104 ± 17 mL/min/1.73 m² for whites at baseline. For both blacks and whites, eGFRcys decline was minimal at younger ages (<35 years) and eGFRcys loss accelerated at older ages. However, acceleration of eGFRcys decline occurred at earlier ages for blacks than whites. Blacks had somewhat faster annualized rates of decline compared with whites, but differences were attenuated after adjustment in period 1 (0.13 mL/min/1.73 m² per year faster; P = 0.2). In contrast, during period 2, blacks had significantly faster annualized rates of decline, even after adjustment (0.32 mL/min/1.73 m² per year faster; P = 0.003). The prevalence of rapid decline was significantly higher for blacks versus whites, with prevalence rate ratios of 1.31 (95% CI, 1.04-1.63) for period 1 and 1.24 (95% CI, 1.09-1.41) for period 2. Differences were attenuated after full adjustment: adjusted prevalence rate ratios were 1.20 (95% CI, 0.95-1.49) for period 1 and 1.10 (95% CI, 0.96-1.26) for period 2. LIMITATIONS: No measured GFR. CONCLUSIONS: eGFRcys decline differs by race at early ages, with faster annualized rates of decline for blacks. Future studies are required to explain the observed differences.
Authors: Paul Muntner; Britt Newsome; Holly Kramer; Carmen A Peralta; Yongin Kim; David R Jacobs; Catarina I Kiefe; Cora E Lewis Journal: Clin J Am Soc Nephrol Date: 2011-11-10 Impact factor: 8.237
Authors: Carmen A Peralta; Ronit Katz; Ian DeBoer; Joachim Ix; Mark Sarnak; Holly Kramer; David Siscovick; Steven Shea; Moyses Szklo; Michael Shlipak Journal: J Am Soc Nephrol Date: 2011-06-23 Impact factor: 10.121
Authors: Michael G Shlipak; Mark J Sarnak; Ronit Katz; Linda F Fried; Stephen L Seliger; Anne B Newman; David S Siscovick; Catherine Stehman-Breen Journal: N Engl J Med Date: 2005-05-19 Impact factor: 91.245
Authors: Bruce A Perkins; Robert G Nelson; Betsy E P Ostrander; Kristina L Blouch; Andrzej S Krolewski; Bryan D Myers; James H Warram Journal: J Am Soc Nephrol Date: 2005-03-23 Impact factor: 10.121
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: G D Friedman; G R Cutter; R P Donahue; G H Hughes; S B Hulley; D R Jacobs; K Liu; P J Savage Journal: J Clin Epidemiol Date: 1988 Impact factor: 6.437
Authors: Leila R Zelnick; Ronit Katz; Bessie A Young; Adolfo Correa; Bryan R Kestenbaum; Ian H de Boer; Nisha Bansal Journal: Am J Kidney Dis Date: 2017-01-28 Impact factor: 8.860
Authors: Afshin Parsa; W H Linda Kao; Dawei Xie; Brad C Astor; Man Li; Chi-yuan Hsu; Harold I Feldman; Rulan S Parekh; John W Kusek; Tom H Greene; Jeffrey C Fink; Amanda H Anderson; Michael J Choi; Jackson T Wright; James P Lash; Barry I Freedman; Akinlolu Ojo; Cheryl A Winkler; Dominic S Raj; Jeffrey B Kopp; Jiang He; Nancy G Jensvold; Kaixiang Tao; Michael S Lipkowitz; Lawrence J Appel Journal: N Engl J Med Date: 2013-11-09 Impact factor: 91.245
Authors: May A Beydoun; Angedith Poggi-Burke; Alan B Zonderman; Ola S Rostant; Michele K Evans; Deidra C Crews Journal: Psychosom Med Date: 2017-09 Impact factor: 4.312
Authors: Deidra C Crews; Tanushree Banerjee; Donald E Wesson; Hal Morgenstern; Rajiv Saran; Nilka Ríos Burrows; Desmond E Williams; Neil R Powe Journal: Am J Nephrol Date: 2018-03-09 Impact factor: 3.754
Authors: Omar Niss; Adam Lane; Monika R Asnani; Marianne E Yee; Ashok Raj; Susan Creary; Courtney Fitzhugh; Prasad Bodas; Santosh L Saraf; Sharada Sarnaik; Prasad Devarajan; Punam Malik Journal: Blood Adv Date: 2020-04-14
Authors: Julia Z Xu; Melanie E Garrett; Karen L Soldano; Sean T Chen; Clary B Clish; Allison E Ashley-Koch; Marilyn J Telen Journal: Am J Hematol Date: 2018-09-27 Impact factor: 10.047
Authors: Bessie A Young; Ronit Katz; L Ebony Boulware; Bryan Kestenbaum; Ian H de Boer; Wei Wang; Tibor Fülöp; Nisha Bansal; Cassianne Robinson-Cohen; Michael Griswold; Neil R Powe; Jonathan Himmelfarb; Adolfo Correa Journal: Am J Kidney Dis Date: 2016-04-09 Impact factor: 8.860
Authors: Cristina M Arce; Jinnie J Rhee; Katharine L Cheung; Haley Hedlin; Kristopher Kapphahn; Nora Franceschini; Roberto S Kalil; Lisa W Martin; Lihong Qi; Nawar M Shara; Manisha Desai; Marcia L Stefanick; Wolfgang C Winkelmayer Journal: Am J Kidney Dis Date: 2015-09-01 Impact factor: 8.860